Last reviewed · How we verify
Hyaluronic acid filler/IMD1 basic
Hyaluronic acid filler provides volumization and hydration to facial tissues by integrating into the dermis and binding water molecules.
Hyaluronic acid filler provides volumization and hydration to facial tissues by integrating into the dermis and binding water molecules. Used for Facial wrinkles and folds correction, Lip augmentation, Facial volume restoration.
At a glance
| Generic name | Hyaluronic acid filler/IMD1 basic |
|---|---|
| Sponsor | Merz Pharmaceuticals GmbH |
| Drug class | Dermal filler |
| Modality | Small molecule |
| Therapeutic area | Dermatology/Aesthetics |
| Phase | FDA-approved |
Mechanism of action
Hyaluronic acid is a naturally occurring polysaccharide that acts as a humectant, drawing and retaining water in the skin. When injected as a dermal filler, it physically restores lost volume in facial tissues and simultaneously hydrates the surrounding dermis, smoothing wrinkles and restoring facial contours. The filler gradually biodegrades over time as the body metabolizes the hyaluronic acid.
Approved indications
- Facial wrinkles and folds correction
- Lip augmentation
- Facial volume restoration
Common side effects
- Injection site swelling
- Injection site erythema
- Bruising
- Tenderness at injection site
- Nodule formation
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyaluronic acid filler/IMD1 basic CI brief — competitive landscape report
- Hyaluronic acid filler/IMD1 basic updates RSS · CI watch RSS
- Merz Pharmaceuticals GmbH portfolio CI